Search Results
Your search for The ,The matches 35026 pages
Showing 1 - 50
Case 3: Newly Diagnosed Limited-Stage Small Cell Lung Cancer
This is Part 3 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss treatment of newly diagnosed limited-stage small cell ...
Case 2: Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
This is Part 2 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of newly diagnosed extensive-stage...
Case 1: Relapsed Small Cell Lung Cancer
This is Part 1 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of relapsed small cell lung cancer...
Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer
The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...
Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma
A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...
Surgery vs Ablation in Small Hepatocellular Carcinoma
In two Japanese studies (SURF-RCT and SURF-Cohort) reported in the Journal of Clinical Oncology, Kawaguchi et al compared the outcomes of surgery vs radiofrequency ablation (RFA) in patients with small hepatocellular carcinoma (HCC). Study Details Two multicenter studies were performed, with...
New Research Offers Reassurance About Localized Prostate Cancer Prognosis
A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...
Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial
In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...
RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma
When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...
Literature Review Highlights Rising Incidence and Disparities in Many Early-Onset GI Cancers
Rates of early-onset gastrointestinal cancers, beyond just colorectal cancer, are rising among people younger than age 50, according to experts from Dana-Farber Cancer Institute. Researchers from Dana-Farber published a literature review in the British Journal of Surgery showing that cases of newly ...
A Young Hematologist’s Take on ICML 2025
From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an innovative chemotherapy-free approach to treating lymphoma)—the nostalgia at the International...
AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging
An update of staging guidelines from the American Joint Committee on Cancer (AJCC) for human papillomavirus (HPV)-positive throat cancer—now more common in the United States than cervical cancer, according to the American Cancer Society—aims to make treatment of early-stage disease more consistent...
Ruxolitinib for Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease
In the 3-year final analysis of the phase III REACH3 trial reported in the Journal of Clinical Oncology, Zeiser et al compared the use of ruxolitinib vs best available therapy (BAT) in terms of failure-free survival and duration of response in patients with steroid-refractory or -dependent chronic...
Women Over the Age of 65 Still at Heightened Risk of HPV-Related Cervical Cancer
Women aged 65 years and older are still at a heightened risk of cervical cancer caused by human papillomavirus (HPV), suggest the findings of a large observational Chinese study published by Ye et al in Gynecology and Obstetrics Clinical Medicine. Most guidelines currently recommend discontinuing...
Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC
Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...
The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies
Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease subtype, we have molecularly characterized tumors and developed specific treatment algorithms to optimize patient outcomes. Among...
Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk
Treating drinking water for multiple contaminants, especially arsenic and chromium-6, could prevent more than 50,000 cancer cases in the United States, according to the results of a study by the Environmental Working Group that was published in Environmental Research. Study findings highlighted...
Subsequent Neoplasm Risk Among Childhood Cancer Survivors: Effect of BMI and Physical Activity
In a study reported in JAMA Oncology, Joffe et al examined the association of high body mass index (BMI) and low physical activity with increased risk of subsequent neoplasms among childhood cancer survivors. Study Details The study involved data on 5-year survivors of childhood cancers diagnosed...
Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma
In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD (doxorubicin, vinblastine, dacarbazine; N-AVD) vs brentuximab vedotin plus AVD (BV-AVD) in patients with advanced-stage...
Adult Survivors of Childhood Cancer May Be at Increased Risk of Severe COVID-19 Infection
People who have survived cancer as children may be at a higher risk of developing severe COVID-19 infection—even decades after their cancer diagnosis, according to results published by Louro et al in The Lancet Regional Health – Europe. Thanks to medical advances, more and more children are...
Can Planned C-Sections Increase the Risk of Childhood ALL?
Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they...
BMI and Cardiovascular Disease Associated With Increased Breast Cancer Risk
Weight-associated risk for developing breast cancer after menopause may be higher among women with cardiovascular disease compared with those without cardiovascular disease and women with or without type 2 diabetes, according to the results of two prospective European cohort studies, which were...
Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma
In a phase II trial reported in The Lancet Oncology, Elimova et al evaluated the efficacy and safety of the bispecific monoclonal antibody zanidatamab plus chemotherapy in the first-line treatment of patients with advanced HER2-positive gastroesophageal adenocarcinoma. Study Details In the trial,...
Survey Finds Confusion Over Mammogram Guidelines
Mammograms can detect breast cancer early before symptoms appear, and regular screening decreases the risk of dying from breast cancer. But a recent survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania shows that some Americans appear to be confused about...
Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC
The U.S. Food and Drug Administration (FDA) has approved SIR-Spheres Y-90 resin microspheres, manufactured by Sirtex, for the treatment of unresectable hepatocellular carcinoma (HCC). With this approval, these microspheres become the only radioembolization therapy approved for the treatment of both ...
Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma
In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic,...
Survival Disparities Rise in Patients With Advanced Cancer Depending on Whether They Have Insurance to Cover Immune Checkpoint Inhibitors
A study led by researchers at the American Cancer Society examining the association between the introduction of immune checkpoint inhibitors (ICIs) and changes in survival disparities by health insurance coverage among patients with newly diagnosed stage IV melanoma, non–small cell lung cancer...
Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies
Investigators have bioengineered an organotypic immunocompetent chip—a laboratory device that combines the physical structure of human leukemia bone marrow and a functioning immune system—to empower real-time spatiotemporal monitoring of CAR-T cell functionality for leukemias. The preclinical...
Air Pollution Linked to Distinct Genomic Signatures in Lung Cancers Among Never-Smokers
A large analysis of the mutational processes of lung cancers in never-smoker patients showed that exposure to fine-particulate air pollution was strongly associated with increased genomic changes, including in cancer-driving and cancer-promoting genetic mutations. Findings from the whole-genome...
FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...
Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL
In an Australian phase II trial (COALITION) reported in the Journal of Clinical Oncology, Minson et al investigated the addition of glofitamab to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide,...
Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
In a National Cancer Institute phase II trial reported in The New England Journal of Medicine, Srinivasan et al investigated whether the monoclonal antibody bevacizumab in combination with the EGFR inhibitor erlotinib showed activity in patients with advanced hereditary leiomyomatosis and renal...
PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma
Patients with ovarian clear cell carcinoma harboring PPP2R1A mutations showed significantly improved survival when treated with immunotherapy compared with those without PPP2R1A mutations, according to study findings published in Nature. Preclinical findings from the study also suggested that...
FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...
Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells
Many cytotoxic chemotherapy agents have long-term biological consequences, including premature aging of the cell population structure of healthy blood, the results of a study of the genetic effects of chemotherapy showed. These findings published in Nature Genetics may help to guide future...
Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer
In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity (OIPN) risk associated with lean body mass (LBM)-based oxaliplatin dosing in the adjuvant treatment of stage III colon cancer....
Can Hormone Therapy Affect Breast Cancer Risk in Younger Women?
Investigators have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use this type of hormone therapy. Additionally, women...
Uterine Cancer Incidence and Mortality Rates Projected to Rise Substantially by 2050
Uterine cancer is the fourth most common cancer diagnosed in women in the United States, with about 69,120 new cases and nearly 14,000 deaths from the disease expected this year. Black women experience a twice as high mortality rate compared with women of other races and ethnicities, and that...
AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative
Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and magnetic resonance imaging (MRI) for breast cancer screening, according to study results that were published in Nature...
Erika Hamilton, MD, on Oral SERDs in Breast Cancer: State of the Science
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, provides a look at “where we stand in 2025” in the field of oral selective estrogen receptor degraders (SERDs) for patients with estrogen receptor–positive, HER2-negative breast cancer. She discusses the first...
utDNA May Help to Personalize Bladder Cancer Treatment
Results of a multi-institutional study published by St-Laurent et al in Science Direct revealed that testing urine-based tumor DNA (utDNA) may help to predict which patients with bladder cancer are at higher risk for recurrence after not responding to first-line treatment. The study analyzed utDNA...
Case 3: Recurrent Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
This is Part 3 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the management of recurrent...
Case 2: High-Risk De Novo Metastatic Hormone-Sensitive Prostate Cancer
This is Part 2 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of high-risk de...
Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens
As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (ARPI) in patients with castration-resistant prostate cancer with extrapelvic soft-tissue metastases...
Case 1: De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer With PTEN Deficiency
This is Part 1 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of de novo...
HER3-DXd in NSCLC Without EGFR-Activating Mutations
As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) in patients with advanced squamous or nonsquamous non–small cell lung cancer (NSCLC) without a...
Survey Shows Inaccuracies in U.S. Perceptions of Testicular Cancer
Only about 13% of U.S. adults correctly reported that testicular cancer is most common among men younger than 40, according to the results of a survey. The survey, commissioned by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research...
Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers
The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting. Kidney Cancer: Long-Term...
Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML
In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...
Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes
As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...
